Review of the clinical utility of NT-proBNP in the diagnosis, prognosis, and therapy monitoring of patients with congestive heart failure

Journal of Clinical Ligand Assay

Volumn 25, Issue 2, 2002, Pages 160-166

  Ambrose, Theresa M ^a  

^a Roche Diagnostics Corporation   (United States)

Author keywords

Heart failure; Natriuretic peptides; NT proBNP (N terminal pro brain natriuretic peptide); Risk stratification; Therapy selection

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOGEN RECEPTOR ANTAGONIST; LOOP DIURETIC AGENT; NESIRITIDE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG;

ASSAY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; HEART VENTRICLE OVERLOAD; HUMAN; LABORATORY; MEDICARE; MUSCLE STRETCHING; PATIENT MONITORING; PREVALENCE; PROGNOSIS; REVIEW; RISK ASSESSMENT; TREATMENT PLANNING;

EID: 0037633093     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. National Institutes of Health National Heart Lung and Blood Institute Morbidity & Mortality: 2000 Chart Book on Cardiovascular, Lung, and Blood Diseases. National Institutes of Health. www.nhlbi.nih.Rov/resources/docs/cht-book.htm
2. Kirkwood F, Adams J: New epidemiologic perspectives concerning mild-to-moderate heart failure. Am J Med 2001;110:6S-13S.
3. Remme WJ, Swedberg K: Task Force Report: Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-1560.
4. Braunwald E: Congestive heart failure: a half century perspective. Eur Heart J 2001;22:825-836.
5. McKee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of congestive heart failure: the Framingham study. N Engl J Med 1971;285:1441-6.
6. Remes JMH, Reunamen APK: Validity of clinical diagnosis of heart failure in primary health care. Eur Heart J 1991;12:315-321.
7. Struthers AD: The diagnosis of heart failure. Heart 2000;84:334-338.
8. McCullough PA , Novak RM, McCord J, et al: B-type natriuretic peptide adds to clinical judgement in the diagnosis of heart failure: a Bayesian analysis from the BNP multinational study. J Am Coll Cardiol 2002;39:140A
9. McNamara RL, Lima JA, Whelton PK, Powe NR: Echocardiographic identification of cardiovascular sources of emboli to guide clinical management of stroke: A cost-effectiveness analysis. Annals of Internal Med 1997;127:775-787.
10. Cooley E: Newer drug therapy for congestive heart failure. Arch Intern Med 1999;159:1177-183.
11. Oxenham H, Sharpe N: Prognostic stratification in heart failure: What's the point? Eur Heart J 2000;21:1815-1816.
12. Valli N, Gobinet A, Bordenave L: Review of 10 years of the clinical use of brain natriuretic peptide in cardiology. J Lab Clin Med 1999;134:437-444.
13. Clerico A, Iervasi G, Mariani G: Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-498.
14. Sagnella G: Measurement and significance of circulation natriuretic peptides in cardiovascular disease. Clin Sci 1998;95:519-529.
15. Mair J, Friedl W, Thomas S, Puschendorf B: Natriuretic peptides in assessment of left-ventricular dysfunction. Scan J Clin Lab Invest 1999;59:132-142.
16. Triage BNP product insert. Biosite Diagnostics, Inc. San Diego, CA, 1999.
17. Hunt P, Richards A, Nicholls M, Yandle TG, Doughty R, Espiner EA: Immunoreactive amino t-terminal pro-brain natriuretic peptide (NT-PROBNP): A new marker of cardiac impairment. Clin Endocr 1997;47:287-296.
18. Downie PF, Talwar S, Squire IB, Davies JE, Barnett DB, Ng LL: Assessment of the stability of N-terminal pro-brain natriuretic peptide in vitro: implications for assessment of left ventricular dysfunction. Clin Sci 1999;97:255-258.
19. Sokoll L, Baun H, Collinson P, et al: Performance evaluation of Elecsys proBNP in a multicenter study topic. Clin Chem 2002;48:A91
20. Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H: Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin Chim Acta 2001;305:181-186.
21. Wu AHB: B-Type Natriuretic Peptide for Congestive Heart Failure. JCLA 2002;25:155-159.
22. McDonagh TA, Morton JJ, Baumann M, Trawisnki J, Dargie HJ. N-terminal proBNP: Role in the diagnosis of left ventricular dysfunction in a population-based study. J Cardiac Fail 2000;6:23
23. Hammerer-Lercher A, Neubauer E, Mueller S, Pachinger O, Puschendorf B, Mair J: Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 2001;310:193-197.
24. Sirithunyanont C, Leowattana W, Sukumalchantra Y, et al: Role of the plasma brain natriuretic peptide (NT-proBNP) in differentiating patients with congestive heart failure from other diseases. Abstract Book, The Heart Association of Thailand under the Royal Patronage, 34th Annual Scientific Meeting, 27-29 March 2002.
25. Groenning BA, Raymond I, Pederen F, et al: N-terminal pro brain natriuretic peptide concentrations in the diagnosis of heart failure in the general population. Eur J Heart Failure 2000;3:95
26. Richards AM, Doughty R, Nicholls MG, et al: Plasma N-terminal pro brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 2001;37:1781-1787.
27. Hartmann F, Packer M, Coats AJ, et al: Prognostic impact of plasma NT-proBNP in Severe congestive heart failure. The NT-proBNP COPERNICUS substudy. Circulation 2002;Manuscript submitted.
28. Hamm CW, Heeschen C, Goldman B, et al: Benefit of abciximab in patients with refractory unstable angina in relation to serum Troponin T levels. N Eng J Med 1999;340:1623-1629.
29. Newby LK, Ohman EM, Chrsitenson RH, et al: Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin-T positive status: The PARAGON-B Troponin T substudy. Circulation 2001;103:2891-2896.
30. Heeschen C, Hamm CE, Goldmann B, Dey A, Langenbrinck L, White HD: Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficiency of tirofiban. Lancet 1999;354:1757-1762.
31. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nichollls MG, Richards AM: Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-1130.
32. Maisel AS: B-Type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Failure 2001;7:183-193.
33. Cheng V, Kazanagra R, Garcia A, et al: A rapid bedside test for B-type natriuretic peptide predicts treatment outcomes in patients admitted for decompensated heart failure. J Am Coll Cardiol 2001;37:386-391.
34. Kazanegra R, Cheng V, Garcia A, et al: A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: A pilot study. J Cardiac Failure 2001;7:21-29.
35. The Joint European Society of Cardiology/American College of Cardiology Committee. Myocardial Infarction Redefined - A Consensus Document of the Joint ESC/ACC Committee for the Redefinition of Myocardial Infarction. J Am Coll Cardiol 2000;36:959-969.
36. Redfield MM, Rodeheffer RJ, Mahoney DW, Jacobsen SJ, Burnett JC: Plasma BNP to screen for systolic dysfunction in the community: Importance of using age- and sex-specific partition values. J Am Coll Cardiol 2002;39:200A-201A.